|DB00734||Risperidone||Risperidone belongs to the class of medications known as second generation atypical antipsychotics [A1114, A1115, L1213]. It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [A1115, A1116, L1212, L1213].|
|DB00863||Ranitidine||Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).|
|DB00960||Pindolol||For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.|
|DB00455||Loratadine||A self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian).|
|DB00540||Nortriptyline||Primarily indicated for the relief of symptoms of depression.|
|DB00571||Propranolol||For the prophylaxis of migraine.|
|DB00619||Imatinib||For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).|
|DB00334||Olanzapine||For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.|
|DB01023||Felodipine||For the treatment of mild to moderate essential hypertension. |
|DB00448||Lansoprazole||For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.|
|DB00358||Mefloquine||For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.|
|DB00338||Omeprazole||Omeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis. |
|DB01062||Oxybutynin||For the treatment of overactive bladder.|
|DB01087||Primaquine||For the treatment of malaria.|
|DB01037||Selegiline||Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.|
|DB00763||Methimazole||For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.|
|DB00661||Verapamil||For the treatment of hypertension, angina, and cluster headache prophylaxis.|
|DB00570||Vinblastine||For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.|
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998].
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011].
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011].
For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011].
For the treatment of recurrent ovarian cancer [L2011].
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011].
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].
|DB06287||Temsirolimus||For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.|
|DB01129||Rabeprazole||For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.|
|DB06589||Pazopanib||Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
|DB06512||Deramciclane||Investigated for use/treatment in anxiety disorders.|
|DB00022||Peginterferon alfa-2b||Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|DB00494||Entacapone||Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".|
|DB04938||Ospemifene||Ospemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.|
|DB00285||Venlafaxine||For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.|
|DB01175||Escitalopram||Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients. |
|DB00921||Buprenorphine||For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.|
|DB00381||Amlodipine||For the treatment of hypertension and chronic stable angina.|
|DB09065||Cobicistat||Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.|
|DB00246||Ziprasidone||In it's oral form, ziprasidone is approved for the treatment of Schizophrenia and Bipolar I disorder while the injectable formulation is approved for treatment of acute agitation in schizophrenia.|
|DB09238||Manidipine||For the treatment of hypertension.|
|DB00321||Amitriptyline||This drug in indicated for the following conditions [FDA label]:
Major depressive disorder in adults
Management of neuropathic pain in adults
Prophylactic treatment of chronic tension-type headache (CTTH) in adults
Prophylactic treatment of migraine in adults
Treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis [FDA label]
Off-label uses: irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation, fibromyalgia, and insomnia |
|DB00458||Imipramine||For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label].
May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904]. |
|DB09167||Dosulepin||Indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required.|
- Indicated for the treatment of depression and/or anxiety [FDA Label].
- Indicated for the treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders [FDA Label].
- Indicated for the treatment of insomnia characterized by difficulties with sleep maintenance [L1347].
- Indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus [L1344].|
|DB01151||Desipramine||For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management. |
|DB08881||Vemurafenib||Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271]
Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]|
|DB00908||Quinidine||For the treatment of ventricular pre-excitation and cardiac dysrhythmias|
|DB00215||Citalopram||For the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].|
|DB00501||Cimetidine||For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.|
|DB00234||Reboxetine||For the treatment of clinical depression.|
|DB00238||Nevirapine||For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.|
|DB00623||Fluphenazine||For management of manifestations of psychotic disorders.|
|DB00613||Amodiaquine||For treatment of acute malarial attacks in non-immune subjects.|
|DB00967||Desloratadine||For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.|
|DB00972||Azelastine||For the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.|
|DB01131||Proguanil||For the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world.|
|DB01149||Nefazodone||For the treatment of depression.|
|DB01191||Dexfenfluramine||For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet|
|DB01628||Etoricoxib||For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.|
|DB01093||Dimethyl sulfoxide||For the symptomatic relief of patients with interstitial cystitis.|
|DB00625||Efavirenz||For use in combination treatment of HIV infection (AIDS)|
|DB00751||Epinastine||For the prevention of itching associated with allergic conjunctivitis.|
|DB00227||Lovastatin||Lovastatin is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.[FDA label]
In individuals with risk factors related to elevated total cholesterol, elevated LDL cholesterol and below average HDL cholesterol, lovastatin can be used to reduce the risk of myocardial infarction, unstable angina and coronary revascularization procedures.[FDA label]
As well, lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease.[FDA label]
Lovastatin is used as part of the multiple risk factor intervention with a saturated fat-restricted diet in patients with significantly increased risk of atherosclerotic vascular disease due to hypercholesterolemia. The administration of lovastatin is restricted to patients to whom the administration of a diet restricted in saturated fat and cholesterol or the application of nonpharmaceutical measures are inadequate or irresponsive.[FDA label]
Lovastatin is indicated as an adjunct therapy to diet to reduce total cholesterol, LDL cholesterol and apolipoprotein B level in adolescents between 10-17 years. The administration of lovastatin is restricted to patients in which adequate diet has been unresponsive as seen by LDL cholesterol higher than 189 mg/dL or LDL cholesterol higher than 160 mg/dL and history of family cardiovascular disease or with two or more cardiovascular disease risk factors.[FDA label]
Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed.[FDA label]
Lovastatin is used off-label for the treatment and management of peripheral artery disease.[T415]|
|DB00627||Niacin||For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.|
|DB00342||Terfenadine||For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.|
|DB01232||Saquinavir||For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.|
|DB00209||Trospium||For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.|
|DB00317||Gefitinib||For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.|
|DB01206||Lomustine||For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.|
|DB01323||St. John's Wort||Not Available|
|DB01255||Lisdexamfetamine||For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246].
This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].